{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:06Z","timestamp":1759017966884,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.annder.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T20:17:22Z","timestamp":1551471442000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["D\u00e9tection et impact d\u2019une s\u00e9ropositivit\u00e9 VIH chez les patients atteints de psoriasis. Une enqu\u00eate de pratiques"],"prefix":"10.1016","volume":"146","author":[{"given":"M.","family":"Guignant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-B.","family":"Duval-Modeste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vermersch-Langlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.01.008_bib0190","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1468-3083.2012.04563.x","article-title":"Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus","volume":"27","author":"Kanada","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.01.008_bib0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/108729100317696","article-title":"HIV-associated psoriasis","volume":"14","author":"Mallon","year":"2000","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.annder.2019.01.008_bib0200","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/j.revmed.2008.10.004","article-title":"\u00c9pid\u00e9miologie de l\u2019infection \u00e0 VIH en France et en Europe","volume":"29","author":"Costagliola","year":"2008","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2019.01.008_bib0205","unstructured":"ECN.PILLY 2018\u00a0UE6\u00a0N(165\u00a0Infection \u00e0 VIH)\u00a0; 2018 [Internet]. http:\/\/www.infectiologie.com\/UserFiles\/File\/formation\/ecn-pilly-2018\/ecn-2018-ue6-165-nb.pdf [consult\u00e9 le 19\u00a0nov 2017]"},{"key":"10.1016\/j.annder.2019.01.008_bib0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Menon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.clindermatol.2004.07.007","article-title":"Cutaneous markers of HIV infection","volume":"22","author":"Rigopoulos","year":"2004","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0220","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.4067\/S0716-10182015000100005","article-title":"Dermatologic manifestations associated with HIV\/AIDS","volume":"32","author":"Navarrete-Dechent","year":"2015","journal-title":"Rev Chilena Infectol"},{"key":"10.1016\/j.annder.2019.01.008_bib0225","first-page":"1","article-title":"Dermatological management of human immunodeficiency virus (HIV)","volume":"12","author":"Bartlett","year":"2007","journal-title":"Skin Ther Lett"},{"key":"10.1016\/j.annder.2019.01.008_bib0230","first-page":"117","article-title":"Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis","volume":"82","author":"Patel","year":"2008","journal-title":"Cutis"},{"key":"10.1016\/j.annder.2019.01.008_bib0235","unstructured":"Lot F, Sant\u00e9 Publique France. D\u00e9couvertes de s\u00e9ropositivit\u00e9 VIH et de sida. Point \u00e9pid\u00e9miologique du 23\u00a0mars 2017\u00a0; 2017 [Internet]. http:\/\/invs.santepubliquefrance.fr\/Dossiers-thematiques\/Maladies-infectieuses\/VIH-sida-IST\/Infection-a-VIH-et-sida\/Actualites\/Decouvertes-de-seropositivite-VIH-et-de-sida. -Point-epidemiologique-du-23-mars-2017 [consult\u00e9 13\u00a0nov 2017]"},{"key":"10.1016\/j.annder.2019.01.008_bib0240","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","article-title":"HIV-associated psoriasis: pathogenesis, clinical features, and management","volume":"10","author":"Morar","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.annder.2019.01.008_bib0245","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0190-9622(92)70234-7","article-title":"Psoriasis and human immunodeficiency virus infection","volume":"27","author":"Obuch","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s001050050727","article-title":"HIV-associated psoriasis. Clinical and histological observations in 36\u00a0patients","volume":"49","author":"W\u00f6lfer","year":"1998","journal-title":"Hautarzt"},{"key":"10.1016\/j.annder.2019.01.008_bib0255","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2013Update 2015\u2013Short version\u2013EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.01.008_bib0260","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.01.008_bib0265","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archderm.134.8.1025","article-title":"Ultraviolet therapy and patients with HIV infection","volume":"134","author":"Zmudzka","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0781.1995.tb00148.x","article-title":"Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus","volume":"11","author":"Fotiades","year":"1995","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.annder.2019.01.008_bib0275","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0190-9622(93)70171-O","article-title":"The safety of UVB phototherapy in patients with HIV infection","volume":"29","author":"Meola","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0280","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0190-9622(91)70060-F","article-title":"Effect of PUVA on immunologic and virologic findings in HIV-infected patients","volume":"24","author":"Ranki","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archderm.1997.03890420043005","article-title":"Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection","volume":"133","author":"Buccheri","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.annder.2019.01.008_bib0300","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS","volume":"74","author":"Gallitano","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0305","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/09546634.2011.579085","article-title":"Ustekinumab for the treatment of HIV psoriasis","volume":"23","author":"Paparizos","year":"2012","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2019.01.008_bib0310","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jdv.12531","article-title":"Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection","volume":"29","author":"Saeki","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.01.008_bib0315","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-4632.2005.02642.x","article-title":"Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients","volume":"45","author":"Ting","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0320","article-title":"Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies","volume":"101","author":"Nakamura","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.annder.2019.01.008_bib0325","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2019.01.008_bib0330","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jbspin.2006.05.012","article-title":"Use of infliximab to treat psoriatic arthritis in HIV-positive patients","volume":"74","author":"Sellam","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.annder.2019.01.008_bib0335","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.0007-0963.2004.05885.x","article-title":"Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab","volume":"150","author":"Bartke","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0340","first-page":"1353","article-title":"Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection","volume":"34","author":"Linardaki","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0345","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4065\/75.10.1093","article-title":"Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis","volume":"75","author":"Aboulafia","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.annder.2019.01.008_bib0350","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23\u00a0monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2019.01.008_bib0355","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0360","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/jdv.14406","article-title":"Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort","volume":"31","author":"Sbidian","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.01.008_bib0365","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2009.05.017","article-title":"National Psoriasis Foundation. Cyclosporine and psoriasis: 2008\u00a0National Psoriasis Foundation Consensus Conference","volume":"62","author":"Rosmarin","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.01.008_bib0185","unstructured":"Rapport_Morlat_2013_Mise_en_ligne.pdf\u00a0; 2013 [Internet]. http:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/Rapport_Morlat_2013_Mise_en_ligne.pdf [consult\u00e9 le 19\u00a0nov 2017]"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819300353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819300353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:07:09Z","timestamp":1758971229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819300353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0151963819300353"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.01.008","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9tection et impact d\u2019une s\u00e9ropositivit\u00e9 VIH chez les patients atteints de psoriasis. Une enqu\u00eate de pratiques","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}